Highly effective treatments for pediatric onset MS linked to best outcomes at 2 years

For individuals with pediatric-onset multiple sclerosis, treatment with commonly known highly effective therapies was associated with reduced relapse risk and optimal outcome within the first 2 years, researchers wrote in JAMA Neurology.
“Early treatment after [multiple sclerosis] onset has shown benefits in reducing persistent disability in children,” Nail Benallegue, MD, PhD, of the department of pediatric neurology at Angers University in France, and colleagues wrote. “A common strategy in adult MS and [pediatric onset] MS is to escalate treatment from moderately effective

For individuals with pediatric-onset multiple sclerosis, treatment with commonly known highly effective therapies was associated with reduced relapse risk and optimal outcome within the first 2 years, researchers wrote in JAMA Neurology.
“Early treatment after [multiple sclerosis] onset has shown benefits in reducing persistent disability in children,” Nail Benallegue, MD, PhD, of the department of pediatric neurology at Angers University in France, and colleagues wrote. “A common strategy in adult MS and [pediatric onset] MS is to escalate treatment from moderately effective